IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma

Clinical Trial ID NCT01189383

Rank	Title	Journal	Year	PubWeight™‹?›
1	Interleukin-15 biology and its therapeutic implications in cancer.	Trends Pharmacol Sci	2011	1.64
2	Trial watch: Dendritic cell-based interventions for cancer therapy.	Oncoimmunology	2012	1.51
3	Trial Watch: Immunostimulatory cytokines.	Oncoimmunology	2012	1.19
4	Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1.	Blood	2012	1.02
5	Trial watch: Dendritic cell-based anticancer therapy.	Oncoimmunology	2014	0.90
6	Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12.	Semin Oncol	2015	0.89
7	Optimizing dendritic cell-based approaches for cancer immunotherapy.	Yale J Biol Med	2014	0.85
8	Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines.	Front Immunol	2016	0.78
9	KLRG1(+) natural killer cells protect against pulmonary metastatic disease by immunosurveillance.	Oncoimmunology	2014	0.75